What is the recommended dosing of oral ceftibuten for uncomplicated enteric fever in an otherwise healthy adult, and when should alternative agents such as cefixime, azithromycin, or intravenous ceftriaxone be preferred?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 21, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ceftibuten is NOT recommended for enteric fever treatment

Ceftibuten has no established role in the treatment of enteric fever and should not be used. The available evidence does not support its use for this indication, and superior alternatives with proven efficacy are readily available.

Why Ceftibuten Should Not Be Used

The provided evidence contains no data whatsoever supporting ceftibuten's efficacy in enteric fever. While ceftibuten is an oral third-generation cephalosporin with activity against various gram-negative organisms 1, 2, its approved indications are limited to:

  • Urinary tract infections
  • Otitis media
  • Pharyngitis/tonsillitis
  • Acute exacerbations of chronic bronchitis
  • Uncomplicated gonorrhea 3

Enteric fever is conspicuously absent from this list.

Recommended Treatment Options Instead

First-Line: Azithromycin

For uncomplicated enteric fever in otherwise healthy adults, azithromycin is the preferred oral agent based on WHO recommendations and the most recent high-quality evidence 4:

  • Dosing: 20 mg/kg once daily (maximum 1 g) for 7 days
  • Evidence: Lower clinical failure rates (OR 0.48) and shorter hospital stays compared to fluoroquinolones 4
  • Recent validation: A 2026 trial of 1,831 participants confirmed azithromycin monotherapy as effective, with 5.1% treatment failure rate 5
  • Relapse rate: <3% 6

Alternative Oral Option: Cefixime (with important caveats)

Cefixime 400 mg daily can be used but has significant limitations 6:

  • Treatment failure rates: 4-37.6% reported 6
  • Inferior to fluoroquinolones: When compared directly, cefixime showed increased clinical failure (RR 13.39), microbiological failure (RR 4.07), relapse (RR 4.45), and longer fever clearance time (+1.74 days) 7
  • When to consider: Only if azithromycin is unavailable or contraindicated, and resistance patterns permit

Intravenous Option: Ceftriaxone

For patients requiring IV therapy or with severe disease, ceftriaxone is preferred 6, 8:

  • Dosing: 2-4 g IV once daily for adults; 50-75 mg/kg/day for children (up to 4 g/day)
  • Duration: 14 days to reduce relapse risk 6
  • Relapse rate: <8% 6
  • Universal susceptibility: All S. typhi and S. paratyphi isolates reported to UK HPA in 2006 were sensitive 6

Clinical Decision Algorithm

Choose based on:

  1. Disease severity:

    • Uncomplicated, stable patient → Oral azithromycin
    • Unstable, severe, or complicated → IV ceftriaxone 6
  2. Geographic resistance patterns:

    • 70% of isolates from Asia are fluoroquinolone-resistant 6

    • Ceftriaxone remains universally effective
    • Azithromycin resistance currently rare 6
  3. Route preference:

    • Oral therapy possible → Azithromycin first-line
    • IV required → Ceftriaxone

Critical Pitfalls to Avoid

  • Do not use ceftibuten - no evidence base for enteric fever
  • Do not use fluoroquinolones empirically in patients from Asia without susceptibility data (>70% resistance) 6
  • Do not use ciprofloxacin disc testing alone - must also test nalidixic acid sensitivity to confirm true fluoroquinolone susceptibility 6
  • Do not add cefixime to azithromycin - a 2026 trial showed no benefit from combination therapy 5
  • Do not treat for <14 days - shorter courses increase relapse risk 6

Recent Evidence Clarification

The 2026 ACT-South Asia trial definitively showed that adding cefixime to azithromycin provides no benefit over azithromycin alone (treatment failure 5.1% in both groups), supporting WHO's recommendation for azithromycin monotherapy 5. This has important antimicrobial stewardship implications.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.